

Gamifant (emapalumab)	
<p>Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials</p> <p><i>Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)</i></p>	<p>Oral presentation</p> <p>Session title: <i>Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis</i></p> <p>Session date: Thursday 12 June</p> <p>Session time: 10:30 - 12:00 CEST</p> <p>Presentation time: 10:48 - 10:57 CEST</p> <p>Location: Room 6.1</p>
<p>Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease</p> <p><i>Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)</i></p>	<p>Poster presentation</p> <p>Session title: <i>Poster View VI</i></p> <p>Session date: Friday 13 June</p> <p>Session time: 12:00 – 13:30 CEST</p> <p>Location: Poster Hall</p>
NASP (formerly SEL-212)	
<p>Variations in uncontrolled gout between Rheumatologists and Nephrologists</p>	<p>Poster presentation</p> <p>Session title: <i>Poster View VIII</i></p> <p>Session date: Friday 13 June</p> <p>Session time: 10:15 - 11:45 CEST</p> <p>Location: Poster Hall</p>
Vonjo (pacritinib)	
<p>Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research</p>	<p>Poster presentation</p> <p>Session title: <i>Poster View VII</i></p> <p>Session date: Friday 13 June</p> <p>Session time: 14 :45 - 15 :45 CEST</p> <p>Location: Poster Hall</p>
<p>PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome</p>	<p>Poster tour</p> <p>Session Title: <i>Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS</i></p> <p>Session date: Saturday 14 June</p> <p>Session time: 10:15 -11:45 CEST</p> <p>Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)</p> <p>Location: Poster Tour II</p>
<p>Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)</p>	<p>Poster tour</p> <p>Session title: <i>Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS</i></p> <p>Session date: Saturday 14 June</p> <p>Session time: 10:15 - 11:45 CEST</p> <p>Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)</p> <p>Location: Poster Tour II</p>
<p>Medical Symposium</p> <p>An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A</p>	<p>Symposium title: <i>Putting on your VEXAS goggles: Seeing what's in plain sight</i></p> <p>Session date: Friday 13 June</p> <p>Session time: 17:30 - 18:30 CEST</p> <p>Location: Fira de Barcelona, Room B4</p>